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Abstract  
In the United States, prevalence of Alzheimer’s Disease (AD) is rising, with an expected increase 
from 5.7 to 14 million patients by 2050. Characterized by the accumulation of amyloid-beta 
plaques in the brain, AD results in loss of cognitive and motor functions, with a theorized link to 
metabolism and ATP production. This study used transgenic AD-model and metabolic mutant 
Caenorhabditis elegans to investigate punicalagin and coenzyme Q10 as possible treatments 
through behavioral and ATP-quantifying assays. Both treatments were successful in rescuing 
chemosensory ability in AD model and metabolic mutant strains. The ability to rescue both 
model systems with each treatment suggests a metabolic deficiency resulting in olfactory 
dysfunction. Punicalagin and coenzyme Q10 rescued mobility in AD and coq-3 worms, 
respectively.  
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1. Background  
1.1 Metabolism and its role in disorder  
 1.1.1 Overview of Metabolism  
 Metabolism is defined as all of the reactions that occur within an organism. Some of 
these reactions produce energy while others produce the building blocks of life such as amino 
acids, fatty acids, and nucleotides. The most active sites for metabolic process are located in the 
liver, brain, and muscles. Energy production is facilitated by digestion and the cellular processes 
involved in the breakdown of food and the processing and storage of metabolites. There are three 
stages that turn food into energy. The first stage is the breakdown of food through digestion, the 
intestines absorb it and then the circulatory system distributes it. The second stage occurs on the 
cellular level. Within the cells, simple sugars, lipids, fatty acids and amino acids are broken 
down into metabolites. This step subsequently produce a small amount of the cell’s total energy 
(Wildman and Medeiros, 2015). The third step is when the metabolites produced in the second 
step are converted into carbon dioxide and water producing most of the cell’s energy. 
 There are two types of metabolic pathways involved in the process by which organisms 
produce energy. These two different processes are known as catabolism and anabolism. 
Catabolism is the breakdown of large compounds into smaller ones while anabolism is the 
building of larger compounds from smaller ones. Metabolic pathways are never truly inactive 
since they produce important biological molecules in all cell types. The main energy producing 
organelle within most complex cell types is the mitochondrion (Wildman and Medeiros, 2015). 
This organelle has a variety of localized transmembrane complexes present that facilitate in the 
production of energy molecules such as adenosine triphosphate (ATP), nicotinamide adenine 
dinucleotide phosphate (NADPH), nicotinamide dinucleotide phosphate (NADH), and flavin 
adenine dinucleotide (FADH2). These four molecules are all produced in the mitochondria, but 
have a variety of purposes throughout the cell. ATP is the fundamental energy molecule that is 
used throughout most cell types of complex organisms. NADPH delivers energy for use in a 
variety of biosynthetic pathways. Lastly, NADH and FADH2 carry energy during the production 
of ATP as well as being a source of energy in certain pathways (Wildman and Medeiros, 2015).   
Out of the many molecules the body uses as energy molecules, the most significant is 
ATP. The goal of the reactions within the mitochondria is to produce this molecule. ATP is 
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composed of three phosphate groups bound to adenosine. However, when one of the bonds 
between the phosphates is broken it produces a large amount of energy as can be seen in Figure 
1.1. Once this occurs the ATP molecule is converted to ADP (adenosine diphosphate) followed 
by AMP (adenosine monophosphate) through another bond breaking reaction. These molecules 
are typically in equilibrium with one another. For example, within a cell the ADP will bind 
pyrophosphate to form ATP to be used in a variety of other processes (Wildman and Medeiros, 
2015). Throughout each cell the concentration of ATP is generally low but variable, rather than 
long term as it is constantly being used in a variety of processes.  
 
Figure 1.1: An Equilibrium diagram of ATP conversion to ADP (Muessig, 2013). This depicts that when ATP is 
used it loses a phosphate group and is converted to ADP. This molecule will then be later condensed to ATP in a 
variety of reactions.  
 NADH, FADH2, and NADH are used throughout the production of ATP in a variety of 
ways within the mitochondria, and are found in multiple other biosynthetic pathways as well. As 
nutrients are broken down, high energy electrons are released and need to travel from that 
location to the location of ATP production. These electrons travel from the site of nutrient 
breakdown to the site of ATP synthesis through the use of NADH and FADH2. NAD
+ is able to 
accept two high energy electrons and two hydrogen ions, forming NADH. Due to this ability, 
NADH is involved in several energy transfer reactions. FAD is converted into FADH2 when it 
accepts two electrons and two protons. These two electron-accepting molecules are involved in a 
variety of similar reactions. NADPH is a molecule that has a similar purpose to the two 
previously mentioned molecules. This molecule in particular is an energy carrying molecule that 
 3 
 
delivers energy to biosynthetic pathways. NADPH is structurally different from NADH because 
of an additional phosphate group, which causes these two molecules to have two different 
functions. NADPH drives biosynthetic processes and as this occurs it releases two highly 
charged electrons (Wildman and Medeiros, 2015).    
 1.1.2 The Electron Transport Chain  
 One of the most important aspects of cellular energy production is the electron transport 
chain, mainly due to the fact that this process is coupled with oxidative phosphorylation which is 
required to produce ATP. The electron transport chain is a series of redox reactions that occur as 
the electrons are passed between the four complexes (Karp, 2008). These reactions are coupled 
with the transfer of protons across the membrane to produce an electrochemical gradient. There 
are four membrane bound complexes named Complex I, Complex II, Complex III, and Complex 
IV that are responsible for the series of reactions involved in this process. All of these complexes 
are located on the inner mitochondrial membrane adjacent to the protein responsible for 
oxidative phosphorylation, ATP synthase (Figure 1.2 below) (Berg, 2002). 
 
Figure 1.2: A Diagram of the Electron Transport Chain coupled with Oxidative Phosphorylation. Protons are 
moved across a membrane as a variety of reactions occur. The proton then enter ATP synthase which uses them to 
convert ADP to ATP (Picture created by: Consedine, 2018).   
Three out of the four complexes (Complex I, Complex III, and Complex IV) involved in 
the electron transport chain are proton pumps and are solely responsible for pushing protons 
across the inner membrane in order to create an electrochemical gradient (Karp, 2008). Multi 
celled organism use oxidative phosphorylation to produce a large amount of energy is produced. 
However it is important to note that less complex organisms such as yeast can produce energy 
through fermentation. Each of the four complexes involved in the electron transport chain has a 
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specific, unique function that lead to the production of ATP through oxidative phosphorylation 
(Alberts et al., 2002). 
Complex I contains a single molecule of flavin mononucleotide (FMN) which is also 
composed of eight or nine of iron clusters. The most common forms of these clusters is [2Fe-2S] 
and [4Fe-4S]. This particular complex has seven [4Fe-4S] and two [2Fe-2S]. The FMN is located 
at the end of a solvent exposed cavity, which is believed to form the NADH binding site. Some 
of the [4FE-4S] clusters form a binding site for the coenzyme Q molecule (coQ) (Alberts et al., 
2002). At Complex I two electrons are removed from NADH and transferred to coQ, thus 
producing QH2 as a product. This product (QH2) is allowed to freely diffuse across the inner 
membrane and transfer four protons to the intermembrane space, which begins the formation of 
the proton gradient. This “proton pumping” mechanism is driven by a conformational change in 
Complex I, which is the result of the change in the redox state of the protein (Voet, Voet & Pratt, 
2012). This complex is the site of a sizeable amount of electron leakage due to the high attraction 
between free electrons and oxygen.   
Complex II is commonly known as succinate-coenzyme Q oxidoreductase and contains 
four subunits. This complex participates in both the electron transport chain and the citric acid 
cycle. Complex II contains a covalently bonded FAD molecule, one [4Fe-4S], one [3Fe-4S], one 
[2Fe-2S], and one cytochrome molecule (Voet, Voet, & Pratt, 2012). At this complex, succinate 
(which is a product of the citric acid cycle) transfers electrons to coQ. The free energy created 
from this reaction is unable to drive ATP synthesis on its own. Unlike Complex I, no protons are 
transferred into the intermembrane space as a result of the electron transfer, thus, this complex 
overall transfers less energy (Berg, 2002).  
Complex III, also known as coenzyme Q-cytochrome c oxidoreductase, contains the 
following molecules: two b-type cytochromes, one cytochrome c, and one [2Fe-2S] cluster. 
Complex III, in particular, contributes to the asymmetric absorption and release of protons. The 
reactions at this complex is a two-step process that allows one molecules of QH2 to transfer its 
electrons to cytochrome c (Berg, 2002). The first reaction permits QH2 to bind and transfer one 
of its electrons to the iron cluster, releasing two protons. Due to this first reaction set, the [2Fe-
2S] iron cluster then reduces one molecule of cytochrome c. The newly formed coQ molecules 
then rebinds to complex III, where it gains another electron to return to a partially reduced state 
(Voet, Voet, & Pratt, 2012). The second reaction set follows a similar manner of reactions, 
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however at the end of this reaction a fully reduced coQ molecule is formed and four protons are 
moved across the membrane.    
 Cytochrome c oxidase, or Complex IV, contains two different cytochrome molecules and 
two different copper atoms. At this complex, two simultaneous reactions occur that affect the 
overall transmembrane proton gradient. As this complex reduces molecular oxygen and produces 
two water molecules, four protons are taken up by the complex (Voet, Voet, & Pratt, 2012). 
Thus, the proton concentration in the matrix is lowered significantly. As this reaction occurs 
these four protons are “pumped” across the membrane in each reaction step. Eight positive 
charges are lost from the matrix to the intermembrane space and contribute to the membrane 
potential difference that drive ATP synthesis (Karp, 2008). Unlike the three other complexes, the 
exact mechanism of action for complex IV is still largely unknown.    
As mentioned previously, the 
electron transport chain is coupled with a 
process called oxidative phosphorylation. 
During this process ATP is produced 
through the use of the electrochemical 
gradient created during the electron 
transport chain and the utilization of the 
FoF1 ATP synthase (Senior, Nadanacvia, & 
Weber, 2002). As can be seen in Figure 
1.3, the protein complex is composed of 
several different sections that all have 
specialized purposes. The Fo protein is 
composed of three subunits called subunits 
a, b, and c and act as an ion channel 
(Jonckheere, Smeitink, & Rodenburg, 
2012). The number of c subunits determines the number of protons that are needed to make the 
Fo turn a full revolution. The number of c subunits is species dependent; in humans eight protons 
are needed, C. elegans require one proton, and mice need four protons.  
In the c subunit, aspartic acid and glutamic acid are present while the a subunit contains 
an arginine residue. All of these residues are highly conserved among species, and believed to 
Figure1.3: A Structural Diagram of the ATP 
Synthase Protein Complex. Protons are moved into 
subunit a which causes subunit c to move which 
allows for the F1 complex to rotate and ATP to be 
produced. (WordPress, 2015) 
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play an important role in proton translocation (Yasuda et al., 1998). The most widely accepted 
model for proton translocation is the “two channel model”. In this model, it is assumed that the a 
subunit has two channels that run half the membrane but on different sides. These channels 
connect the proton binding site with the cytoplasm and each channel is in contact with a different 
c subunit. The proposed mechanism follows this pathway: a proton enters from the cytoplasm 
side and binds to the carboxyl residue in the c subunit (Okuno, Noji, & Lino, 2011). This offsets 
the negative charge on the carboxyl group which allows the c subunit to rotate apart from the a 
subunit toward the lipid bilayer. As this happens, the c subunit at the lipid bilayer makes contact 
with the other half channel. This promotes the deprotonation of the carboxyl residue and the 
proton enters the cytoplasm.  
Once the c subunit is filled, it produces free energy, driving the F1 component of ATP 
synthase and beginning ATP production. The F1 component of ATP synthase is composed of α, 
Β, γ, and ε subunits. The ɑ and Β subunits form a hexamer (Senior, Nadanacvia, & Weber, 
2002). The other subunits involved in this mechanism are part of the rotational component of 
ATP synthase. Subunit B is where ATP is produced and goes through a series of conformational 
changes called the loose state, the tight state, and the open state (Jonckheere, Smeitink, & 
Rodenburg, 2012). Each catalytic site goes through each transition state during a 360° rotation as 
can be seen in Figure 1.4. The mechanism starts by binding adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) to the open state. This subunit then goes into the loose state upon 
binding these molecules. During this same step, the ATP leaves the complex as the 
conformational change occurs and it is now in the open state. ADP and Pi now bind to the newly 
empty open state while the ADP and Pi in the tight are converted into ATP (Nakamoto, Baylis, & 
Al-Shawi, 2008). The process then repeats where the ATP in the tight state leaves as it is now in 
the open state and the whole process begins again. At the end of each rotation three ATP 
molecules are produced as a form of energy for the organism, indicating that each 120° rotation 
produces 1 molecule of ATP.    
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Figure 1.4: A Rotational Diagram of the F1 Subunit in ATP Synthase. ATP and a phosphate group enter 
when one part of the β subunit is open which causes it to convert to the loose state. Once another ADP and 
phosphate group binds, the structure rotates and the first β subunit changes to the tight and converts ADP to ATP. 
the β subunit then rotates which releases the newly made ATP molecule as the β subunit in again in the open state.    
(University of Miami, n.d.) 
1.2: Metabolism and Neurodegeneration in Humans  
1.2.1 Overview of Metabolic Disorders  
  Metabolic diseases alter normal processes which result in biochemical abnormalities 
from a shortage of a particular enzyme or malfunctioning organelle. Most metabolic disorders 
are inherited in an autosomal recessive pattern, but some have been observed to be inherited in x-
linked or autosomal dominant manners. These disorders are further classified into three different 
categories. The first class is composed of disorders defined as the buildup of toxic compounds in 
the organism. The second class are disorders due to low amounts of energy. The third are 
disorders involving complex molecules not involved in the diet. These disorders occur in one in 
every five thousand live births and are considered fairly rare. Generally, metabolic disorders 
have nonspecific symptoms, which means there are no strict set of symptoms that indicate 
someone might have one. The symptoms of metabolic disorders vary from one another since 
they affect different processes in different areas of the organism (Graef, Wolfsdorf, & Greenes, 
2008). Two examples of this are Diabete Mellitus (DM) and Wilson’s Diseases.  
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 DM is a group of metabolic disorders that occurs when the body fails to produce or use 
insulin effectively. There are two types of this disease known as type 1 diabetes or type 2 
diabetes. These two variations of the disease have different causes but result in similar symptoms 
(Brutsaert, 2017). Approximately 347 million people currently live with diabetes mellitus 
worldwide. Type I DM is characterized by the lack of insulin production in the body. The cause 
of type I DM is the autoimmune destruction of pancreatic beta cells. These cells are destroyed 
over months to years and continue until the concentration of glucose in the body can no longer 
be controlled. This type of DM typically occurs in children but can manifest in adults in rare 
cases. (Brutsaert, 2017). Type II DM is characterized by the inability to use insulin properly in 
the body. In this case, the patients have become resistant to insulin and cannot uptake glucose as 
a result. 90% of cases of DM worldwide are type II. The cause of this form of DM is related to 
lack of physical activity and excess body weight. The symptoms for type II DM are extremely 
similar to type I, however unlike type I, type II can occur in both adults and children. If caught 
early enough it is completely treatable with the proper medication, but can go unnoticed for years 
(Brutsaert, 2017).  
Wilson’s Disease is another metabolic disorder that is considered rare as it causes the 
accumulation of copper in vital organs such as the liver or the brain. This disease is an autosomal 
recessive disorder that causes a mutation in the ATP7B gene and it is occurs in approximately 
one in every thirty thousand people.  People are typically diagnosed with Wilson’s Disease 
between the ages of 5 and 35 (Mayo Clinic, n.d.). This disease is technically present at birth but 
symptoms do not begin to manifest until the copper accumulation builds up to significant levels. 
The symptoms of this disease vary depending on the location and severity of copper build up 
(NDDKD, n.d.). Due to the fact that this disease is a genetic disorder, treatment will be a lifelong 
regimen for those that have this disease. Treatment is a two-step process for those that have 
Wilson’s disease. The first is a chelating agents, which bind copper and then causes the organs to 
release all the copper in one’s body which is then filtered out of by the kidneys. The second step 
is taking medication that prevents the buildup of copper from occurring again. With these 
palliative measures this disease is manageable but a lifelong fight for those who live with it 
(Mayo Clinic, n.d.).  
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1.2.2 Neurodegenerative Diseases and Metabolism 
Many diseases that are associated with aging exhibit symptoms that are representative of 
functional loss of nervous and muscular systems, both of which are regulated by metabolism. 
Many patients diagnosed with classical neurological disorders, including Amyotrophic Lateral 
Sclerosis, Huntington’s Disease, and Parkinson’s Disease also exhibit symptoms that directly 
indicate loss of function of key regulatory pathways. This is indicated in symptoms including 
unexplained weight loss, unsteady glucose levels, and lethargy.  
Neurodegenerative disease can present themselves in many different ways. Amyotrophic 
Lateral Sclerosis is classified by the impairment and cell death of motor neurons. Degeneration 
of the motor neurons begins in the cortical nervous system, brainstem and spinal cord. Patients 
with ALS are often found to go into acidosis, which breaks down the lipids in the body (Dodge 
et al., 2013). Parkinson’s Disease also affects motor neurons. Mutations in a series of PARK 
genes cause the buildup of a misfolded protein, α-synuclein that is found at neuronal synapses. 
This causes the neurons responsible in dopamine production to die. Maps of the brains of 
Parkinson’s patients have been created, and it has been found that glucose is metabolized more 
slowly by those affects (Anadahan et al, 2017). Altered metabolism in brains of Parkinson’s 
patients can be seen in Figure 1.5. Huntington’s progressively wipes out both motor and 
cognitive abilities in patients. A mutation in the HTT gene codes for Huntington’s protein. 
Huntington’s proteins lengthens polyglutamate tract with an exon of a repeating CAG mutation. 
One of the key causes of cognitive degeneration in Huntington’s Disease is the impairment of 
over 60 metabolites in the brain (Patasini et al, 2016).  
  
Amyotrophic Lateral Sclerosis, Parkinson’s Disease, and Huntington's Disease are all 
considered classical neurological disorders as the classifying symptoms relate the brain and 
overall degradation of the nervous system. The mechanisms of neurodegeneration vary between 
diseases, but all result in some form of dementia.  Presentation and severity of dementia can vary 
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between diseases, but the 
main characterization is the 
loss of memory and learned 
everyday skills. 
Neurodegeneration is a high 
rate of neuronal cell death 
(Saba, 2015). 
The increased death 
of neuronal cells can be 
directly linked to disruptions 
in the organism’s biological 
function, specifically in the 
electron transport chain and 
energy levels. All cells need 
energy in order to survive. As 
the mitochondria fail, an 
overload of oxidation breaks down the proper transfer energy. When this disruption occurs in the 
mitochondria of neuronal cells, the nervous systems begins to deteriorate at a rapid rate. 
Neurons, unlike other adult cells, do not undergo replication. If a neuron dies, it is not replaced, 
allowing mitochondrial dysregulation to quickly become a problem. Anatomically, Amyotrophic 
Lateral Sclerosis, Parkinson’s Disease, and Huntington’s Disease affect the hypothalamus in the 
brain. This region plays a key role in metabolic functions, as it controls energy transport 
throughout the body (Saba, 2015).  
Currently, doctors do not have any cures for these neurodegenerative disorders. The only 
treatments available are those to relieve symptoms and make patients more comfortable. 
Generally, these medications are only able to target one symptom at a time, making patients take 
a cocktail of various treatments. If doctors are able to find the origin of neuronal cell death, they 
may be able to stop these catastrophic effects (Cai et al, 2012). 
1.2.3 Metabolism in classic Neurodegenerative Disorders: Alzheimer’s Disease  
 Alzheimer’s Disease is a classical neurodegenerative disorder, characterized by the 
degradation of cognitive function and the onset of dementia. In the United States, Alzheimer’s 
Figure 1.5 Metabolic activity in brains of Neurodegenerative Diseases. 
Cross section A is showing the Parkinson's Disease related patterns 
(PDRP), B is the Parkinson’s Disease Cognition Pattern (PDCP), C  is 
the Multiple Systems Atrophy Related Patterns (MSARP), and D is 
Progressive Supranuclear Palsy related pattern. Red is indicative of 
increased metabolism and blue is indicative of decreased. This figure 
was originally published in Meles et al., 2016.  
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Disease is the leading cause of dementia and the 6th leading cause of death. Figure 1.6 shows 
how to condition is spreading across the nation. People can develop Alzheimer’s disease one of 
two ways. Most people develop Alzheimer’s sporadically, however, a small part of the 
population inherit Alzheimer’s disease. The inherited form of Alzheimer’s disease is classified as 
early onset, as most patients develop symptoms before age 65 (Cai et al, 2012). Several genes 
have been linked to Alzheimer’s Disease, but one of the main questions that researchers still 
struggle to understand is how these genes are mutated in the first place (Grant et al., 2013).  
 
Figure 1.6 Map of the United States showing the increase of Alzheimer’s Disease by state as projected to 2025. The 
darker the shade of purple, the higher the growth rate. This image was originally published on the Alzheimer’s 
Association web page (2017).  
 Alzheimer’s disease is characterized by extraneuronal amyloid-β plaque accumulation in 
the brain and neurofibrillary tangles. Amyloid-β peptide (Aβ) is derived from the amyloid 
precursor protein (APP), which is processed by β-secretase and Ɣ-secretase. β-secretase cleaves 
APP into sAPPβ, and Ɣ-secretase cleaves the cytosolic portion of the protein, releasing amyloid-
β. The accumulation of this protein is associated with the progression of neurodegeneration and 
the symptoms of Alzheimer’s Disease (Price, Morris 1999). In addition to neurodegeneration, 
amyloid-β plaques also accumulate in the mitochondrial matrix of cells causing problems in 
energy processing. Most notably is the enzyme alterations occurring at multiple steps in the 
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Kreb’s Cycle that can be identified in those suffering from AD. Improper glucose processing 
toxifies the mitochondria with unhealthy levels of byproduct intermediates (Chen & Yan, 2006).   
Both early onset and non-inherited Alzheimer’s Disease are classified by neurological 
lesions produced through an inherited or developed genetic mutation. The lesions are the Beta 
amyloid plaques and neurofibrillary tangles. Plaques are built up of the beta amyloid proteins, 
and neurofibrillary tangles are built up of the microtubule Tau proteins. Both aggregate in the 
brain and disrupt neurological functions, eventually leading to cell death (Cai et al, 2012). Figure 
1.7 illustrates the accumulation of these proteins in neurons.  
A physical symptom of Alzheimer’s Disease is the degradation of the olfactory system 
resulting in the loss of smell, also known as anosmia. It is believed that the loss of smell is 
occurring in not the peripheral but the central nervous system, as the smells are sending signals 
to the brain but the signals are not being processed correctly (Hawkes, 2003). One of the main 
concerns with measuring anosmia in Alzheimer’s patients is ensuring the loss is an olfactory 
defect as opposed to a cognitive defect. To address these concerns, studies on olfaction have 
been conducted on patients whose memory and mini-mental state examination (MMSE) scores 
show only mild cognitive impairment. These patients were still able to perform normally on 
verbal/visual matching tests. These studies have allowed researchers to determine that the 
anosmia exhibited by those affected by Alzheimer’s 
Disease is more strongly linked to olfactory dysregulation, 
rather than cognitive ability. The presentation of olfactory 
defects in those with mild cognitive impairment validates 
anosmia as an early quasi-diagnostic symptom of 
Alzheimer’s (Luzzi et al., 2006).  
The mitochondria have been identified as a key 
organelle for research. Mitochondria have sparked such 
interest due to their degradation with age, and ability to 
disrupt protein formation and oxidative phosphorylation 
when not functioning properly (Grant et al, 2013).  This 
has caused researchers to propose a new model for 
Alzheimer’s disease. In this new model, Alzheimer’s 
patients have a decreased energy flow from both 
Figure 1.7: Neurological lesions found in 
brains of Alzheimer’s Disease patients. 
(Jin, 2015)  
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glycolysis and oxidative phosphorylation, resulting in increased lactate. When the mitochondria 
detect this decrease of energy flow, they upregulate the oxidative phosphorylation. When this 
increases, it also increases the amount of reactive oxygen in the system. Reactive oxygen are free 
radicals, and they cause oxidative stress. Oxidative stress damages cells, causing DNA damage 
and eventual cell death. If this is happening in the brain, it leads to neurodegeneration 
(Demetrius, Driver, 2013). 
1.2.4 Polyphenols in Therapeutics 
 All plant matter contains a group of compounds called phytochemicals, and are 
responsible for protecting against certain diseases. A type of phytochemical is polyphenols. 
These compounds have a variety of structures but contain one or more phenolic ring. Two 
examples can be seen below in Figure 1.8. Polyphenols can be classified into several different 
categories phenolic acids, flavonoids, phenolic alcohols, stilbenes, and lignans. Polyphenols also 
have “pro-oxidant properties”, which work against their natural metabolic activity (Abbas et al., 
2017). Due to this property, it has the possibility to block cell propagation and apoptosis as well 
as reduce telomerase and lipoxygenase activity.  
 
  
Figure 1.8: Two Examples of different polyphenols.The left shows the compound caffeic acid, a polyphenol naturally 
found in various plant species such as mushrooms, freshwater ferns, and the bark of the Southern Bluegum tree. The 
structure on the right is naringin. It is found in various citrus based fruits, specifically grape fruits.                                                                                                                                                     
To express their biological properties, polyphenols depends heavily on their 
bioavailability. Their structure also determines how fast they are absorbed and the limit of 
absorption in the intestines. Typically polyphenols have one sugar substituent but can have up to 
three, with a wide range of sugars that can be added. Glycosylation, the attachment of sugar 
groups to other functional groups, determines the physical, biological, and chemical properties 
that each polyphenol exhibits. These molecules undergo reactions as they travel throughout an 
organism, specifically in the human small intestine (Abbas et al., 2017). The first reaction occurs 
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as the molecules travel in the small intestine. The polyphenols are digested by various enzymes 
into their more bioavailable metabolite. As they travel, they simultaneously inhibit pathogenic 
microbe growth and promote the growth of beneficial bacteria in the gut microbiome (Manach et 
al., 2004). Both of these result in an overall healthier organism as the more beneficial bacteria 
are more prevalent and the polyphenols are more available for use. 
As such, polyphenols can be used as therapeutic compounds for a variety of diseases and 
illnesses. These disease include, but are not limited to: cardiovascular disease, cancer, 
osteoporosis, neurodegenerative diseases, and diabetes mellitus (Manach et al., 2004). In terms 
of cardiovascular disease, it has been shown that the consumption of polyphenols reduces the 
risk of a cardiac episode. However, there is currently no one polyphenol isolated as a treatment, 
because they all reduce blood pressure, improve the functional capabilities of epithelial tissue, 
and inhibit platelet aggregation by the reduction of lipoprotein. The mechanism of action for 
polyphenols in cardiovascular health has been determined to modulate the activity of nitric oxide 
synthase and its bioavailability, which has an important role in myocardial tissue (Abbas et al., 
2017).   
Through different studies, it has been shown that polyphenols alleviate the side effects of 
type two diabetes in several different ways. One mechanism that has been observed is through 
the inhibition of disaccharides in the intestinal lumen (Anhȇ et al., 2013). This limits the 
digestion of polysaccharides and the absorption of simple sugars by the body. One of the major 
characteristics of type two diabetes is the hyperglycemic condition caused by an increase in 
glucose production and lack of glucose storage. Through the use of polyphenols, glucokinase 
activity increases, increasing glucose storage and decreasing production. Additionally, 
polyphenols have been shown to protect β-islet cells from glucotoxicity, a common side effect of 
hyperglycemia. Generally, polyphenols increase insulin production of the β-islet cells and help to 
stabilize blood glucose levels (Anhȇ et al., 2013).       
When it comes to the brain, studies have shown that both lifestyle and genetic factors the 
development of neurodegenerative diseases and overall cognitive function as age progresses. 
Studies have indicated that those with a high polyphenol diet reduces the risk of dementia and 
improved cognitive function. Specifically catechins, theaflavins, flavonols, and hydroxybenzotic 
acids all have a positive effect on verbal memory and language (Vauzour, 2012).  
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In neurodegenerative diseases such as Alzheimer’s Disease, polyphenols exhibit 
neuroprotective properties. In one study that utilized a mouse AD model, resveratrol, a 
polyphenol found in grapes was shown to increase their cognitive function (Bhullar & 
Rupasinghe, 2013). This compound prevented Aβ formation and protected neurons from Aβ 
toxicity by impeding the enzyme nitric oxide synthase. In a transgenic mouse model, grape 
extracts prevented Aβ oligomerization on a cellular level and generated an increase in cognitive 
function in those mice on a behavioral level. Another study, indicated that the same grape 
extracts prevented the abnormal folding in tau proteins in AD. Another research team showed 
that the metabolite epitachen increased synaptic transmission in the binding protein associated 
with cyclic adenosine monophosphate (cAMP) (Bhullar & Rupasinghe, 2013). Other 
neurodegenerative disorders such as Huntington’s Disease and Parkinson’s Disease have also 
shown to have reduced symptoms when treated with polyphenols. This trend between 
polyphenols and the improvement of patients with neurodegenerative disorders indicates a 
potential new family of therapeutic measures for these diseases. 
1.3 C. elegans as a Model Organism 
 1.3.1 The Life Cycle of C. elegans 
 The study of human biology through the use of model organisms has allowed for 
significant advances in the field of biology. Observation, characterization, and manipulation of 
specific biological processes in non-human organisms have opened windows into the inner 
workings of homologous processes in humans.  
 Caenorhabditis elegans (C. elegans) is a useful model organism for many reasons, the 
most significant of which is its organismal simplicity. These roundworms belong to the 
Chromadorea class of nematodes, are non-parasitic, and measure about 1 mm in length as adults. 
Wild-type C. elegans populations contain mostly hermaphrodites and a miniscule frequency of 
males (one male to every 1,000 hermaphrodites), allowing for self-fertilization and simple 
maintenance of large and genetically homogenous populations. Hermaphrodites carry five 
autosomes and two X chromosomes, while males have the same five autosomes but only one X 
chromosome. The worms themselves are eutelic and anatomically simple. They exhibit a tapered 
outer body tube containing the worm’s dermis, muscular and nervous tissue, and excretory 
organs, and an inner tube containing the worm’s reproductive organs and intestinal tract (Mango, 
2007). The nervous system contains around 300 neurons yet is fairly sophisticated, with both 
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central and peripheral divisions. This grants the worms with the capability of active decision 
making, voluntary motor functions, and neural plasticity (Mango, 2007). 
 The life cycle of C. elegans is divided into 4 larval stages (L1-L4), two adult stages 
(young adult and adult), and two conditional starvation stage (pre-dauer and dauer). Worms with 
adequate amounts of food on their plates progress from the L1 stage to adults in 3.5 days when 
grown at 20°C. Once a hermaphroditic worm reaches adulthood it begins to fertilize oocytes and 
can lay eggs for up to three days, with potentially hundreds of progeny. Under starvation 
conditions, freshly hatched worms enter the L1 arrest stage, which increases the larva’s 
resistance to environmental stressors and stops development (Baugh, 2013). In this state, the 
worm can survive for several weeks without food. Once food is introduced back into the 
environment, the worm exits L1 arrest and returns to the first larval phase (L1) to continue 
development (as seen in Figure 1.9). Dauer formation, however, is more complex--it is induced 
by pheromone signaling from other worms in the vicinity, generally as a result of overcrowding, 
starvation, or high temperature. Unlike L1 arrest, the Dauer stage is associated with a 
morphologic change in the worm’s structure. The worm shrinks in size and feeding behaviors 
and general mobility are greatly suppressed. In this stage, the worm can survive up to 4 months 
without food, and will exit Dauer stage directly to L4 upon encountering a more favorable 
environment with more alimentary resources (Baugh, 2013).  
 
  Figure 1.9: C. elegans life cycle (Wormbook, 2018) 
 Hundreds of worms can be cultured on a single NGM plate seeded with uracil-dependent 
Escherichia Coli OP50, and can be grown at different temperatures to vary both the speed of life 
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cycle and the population fraction of males. While worms are easy to culture and maintain, 
extended storage is also possible through live culture freezing. Original stock worms are 
preserved in M9 and glycerol and are frozen using liquid nitrogen in order to avoid genetic drift 
in extended subcultures in lab (Brenner, 1974). In addition to ease of culture, there is also a 
substantial foundation of research that enables researchers to investigate and manipulate specific 
metabolic processes and genetic loci. C. elegans’ entire genome was sequenced in 1998, and 60-
80% of the encoded genes are homologous to human genes. In addition to this, 40% of human 
genetic diseases have homologous genetic mutations in C. elegans that can simulate analogous 
disease states (Kaletta and Hengartner, 2006). Naturally induced mutations, transgenic 
mutations, and RNAi are all tools that can be used to simulate disease states or conditions, and 
can easily be maintained in hermaphroditic worms.  
 1.3.2 C. elegans as a model for metabolic disorders 
 The simplicity of C. elegans makes it a great platform to model human diseases because 
of the many homologous structures and pathways it shares with humans. Specifically, C. elegans 
can be used as a model for metabolic disorders and imbalances. The wealth of available research 
on C. elegans has allowed scientist to establish comprehensive metabolic network models of 
wild-type metabolism. These models also predict behaviors and outcomes in altered metabolic 
states. Many metabolic pathways and processes in worms are homologous to human pathways, 
such as the electron transport chain, and allows for targeted interventions in C. elegans. Since 
structure and function of each of the mitochondrial complexes are generally highly conserved 
between species, they serve as a good predictor of human mitochondrial function (Moreno-
Arriola et al. 2014) 
 Additionally, C. elegans has been used extensively as a model for oxidative stress and 
related diseases. Modification of the production of radical oxygen species and biological systems 
for oxidative protection allows for deeper investigation into the metabolic mechanisms of stress 
in disease states. One such disease is diabetes mellitus, whose exact mechanisms of 
pathogenicity are not yet fully understood, but exhibits increased mitochondrial production of 
superoxide (O2
*-) (Moreno-Arriola et al. 2014). Worms have similar reactions to oxidative stress 
on a cellular level, and also exhibit the same overproduction of radical oxygen species when 
exposed to glucose. Along with these similarities, C. elegans also contains an insulin-like 
signaling pathway that is involved in the regulation of longevity, metabolism, and growth (Lee et 
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al. 2001). Modeled insulin-deficient worms have been created to study diabetes mellitus that 
exhibit distinct behavioral phenotypic deficits not unlike human diabetic patients. Defective 
insulin production or interruption of the insulin-related growth factor 1 (IGF-1) pathway analog 
DAF-2 results in slowed growth, increased general longevity, and increased longevity of each 
growth stage (Fuchs et al., 2010). Changes in longevity are a common phenotype exhibited in 
metabolic mutants, but are generally difficult to assay in a laboratory setting. Well-established 
behavior patterns in C. elegans serve as excellent baselines to which metabolic mutant activity 
can be compared. 
 1.3.3 C. elegans as a model for AD  
 One of the most apparent parallels between C. elegans and humans is the nervous system, 
which allows for simulation of neurological disorders. One such disorder that can be modeled is 
Alzheimer’s disease (AD). C. elegans express an analogous pathway that cleaves APL-1 instead 
of Aβ. APL-1 and Aβ are similar in both function and sequence, with similarly conserved 
cytosolic, E1, and E2 domains. APL-1, however, doesn’t contain the necessary Aβ domain 
characteristic of the amyloid-β plaques (Alexander et al., 2014). In order to more accurately 
model AD, a transgenic strain was created that encodes the human Aβ1-45, the peptide found in 
amyloid plaques. The first to employ this pathway in C. elegans was Chris Link, who created the 
first AD transgenic C. elegans in order to assess treatment efficacy outside of mammalian 
subjects (Dostal and Link, 2010). 
Transgenic worms that express Aβ in muscular and neuronal tissues do no survive past 
the first larval stage, but specific expression of Aβ in either neuronal or muscular tissue results in 
a viable worm model of AD with cognitive and locomotive impairments, respectively. Both the 
muscular and the neuronal models’ transgenes are expressed at temperatures exceeding 20°C, so 
worms are maintained at 16°C and are heat-shocked at 25°C for expression of Aβ (Dostal and 
Link, 2010). Although typical symptoms of cognitive impairment (such as memory loss) of AD 
cannot be measured in C. elegans, general nervous system integrity and cognitive ability can be 
assessed in a laboratory setting. The worm’s chemosensation relies on amphid sensory cilia and 
sensory neurons to interpret chemical signals and relay them to the worm’s central nervous 
system. Olfactory impairment is a key symptom in AD; many patients present with anosmia in 
early stages of the disease (Olichney et al., 2005). In this way, sensory assays evaluating 
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olfaction in C. elegans serve as a good measure of disease morbidity and allow for the evaluation 
of potential treatments. 
1.4 New Directions: Our Project Overview 
 Previous projects have been able to classify phenotypes in the transgenic worms 
expressing various neurodegenerative disorders through behavioral assays. These phenotypes are 
due to under and over expression of various proteins in the system associated with the individual 
disorders. This project continued forward with treating transgenic Alzheimer’s Disease worms 
with punicalagin, however, the goal of the project was to link Alzheimer’s Disease with an 
electron transport chain defect. To link Alzheimer's Disease with the electron transport chain, 
worms mutated to have deficient electron transport chains were also tested. 
 In order to link Alzheimer’s Disease with defects in the electron transport chain, all of the 
worms needed to be tested under two different treatment conditions, punicalagin and coenzyme 
Q10. Wild-type, transgenic Alzheimer’s, and metabolic mutant worm strains were given OP50, 
OP50 with punicalagin, and OP50 with Coenzyme Q10, and examined with three behavioral 
assays: avoidance, chemotaxis, and locomotion. These behavioral assays provided information in 
order to describe phenotypes of each worm depending on their overexpression of the beta 
amyloid plaques in the nervous system, or under expression of coenzyme in the electron 
transport chain. Following, the worms under each treatment were also tested to determine ATP 
levels via a bioluminescence assay. This allowed the overall energy in the worms to be 
monitored before and after exposure to the various treatments in order to determine if a 
connection is present between Alzheimer’s Disease and an under functional electron transport 
chain.  
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2. Methodology 
2.1 Worm Protocol 
 2.1.1 Maintenance  
C. elegans are maintained on Nematode Growth Medium agar (NGM) in 60 mm plates, 
which allow for growth of large populations sufficient for multiple assays. Each NGM plate was 
seeded with several drops of LB broth inoculated with OP50 E. coli, and were left to dry for 
approximately 24 hours before being used. Once dry, several adults worms from a single strain 
were passed from a parent plate to a new daughter plate using a titanium wire pick. Before 
picking, the wire was sterilized by passing through an open flame. Worms were also moved 
through “chunking”, a method that utilizes a metal spatula (dipped in ethanol and flamed) to slice 
out a small square of agar and transfer the square face down to the daughter plate. Passed plates 
were labeled with the passer’s initials, worm strain, treatment, and the date passed.  
 Once passed, plates were observed frequently in order to maintain a healthy worm line. 
C. elegans growth rates are highly dependent on culture temperature, overcrowding and amount 
of food. If a plate is left to culture for too long, the lack of food will drive worms into the dauer 
stage, leaving no viable adults for testing purposes. In order to ensure a healthy adult population, 
worms were picked every 1-3 generations. If plate contamination became an issue, a few 
different methods can be used to eliminate it, depending on the severity. In the case of mild 
contamination, worms were picked to a seeded plate for one to two days, then after this period of 
time the same worms were then transferred to another seeded plate for culture. If contamination 
was more severe, worm bleaching methods were used. Three gravid adult worms were picked 
from the contaminated plate and placed in a 20�L drop of worm bleaching solution on a fresh 
seeded plate. The solution kills the worms but leaves the eggs intact, which develop once several 
days pass and the bleach evaporates (Stiernagle, 2006). 
2.1.2 Strains  
The N2 strain of C. elegans are a wild-type strain discovered in the 1940s, but were first 
investigated and described by Sydney Brenner in his groundbreaking paper, “The Genetics of 
Caenorhabditis Elegans” in 1973. These worms were gathered from a compost pile in Bristol, 
England in the 1950’s, and serve as a baseline for assays and treatment effects. Worms develop 
fully in 72 hours, and gravid worms can lay upwards of 300 eggs in a lifetime (source). 
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 CL4176 and CL2355 are Alzheimer’s Disease-modeling transgenic strains that produce 
human beta amyloid peptide, one of the main hallmarks for AD. They were chosen because they 
are the closest pathological analog of AD in C. elegans and exhibit similar phenotypic 
characteristics of the disease. Full expression of Aβ in neuronal and muscular worm tissues 
causes the line to be non-viable, so two strains were created: CL4176 (smg-1(cc546) I; dvIs 27 
[myo-3p::A-Beta (1-42)::let-851 3’UTR) + rol-6(su1006)]), with AD gene expression only in the 
muscular tissue, and CL2355 (dvls [pCL45 (snb-1::Abeta 1-42::3’ UTR(long) + mtl-2::GFP]), 
with expression in only neuronal tissue. CL2355 exhibit neuronal deficits, which can be 
observed in chemotaxis and avoidance scenarios, but otherwise develop normally. CL4176 
exhibits muscular impairment at all temperatures; the worms are unable to travel in the normal 
sinusoidal pattern and instead turn in a small circle, with limited control over muscular 
contraction. CL4176 worms are also maintained at 16°C, as higher temperatures modulate gene 
expression--for full expression of Aβ, worms are heat shocked at 25°C. These strains were 
created by Christopher Link at the University Colorado, Boulder in order to study the effects of 
Aβ in living organisms in a high-
throughput testing fashion. (Lublin & 
Link, 2013).  
 Clk-1 (clk-1(e2519) III) is the 
first of the two metabolic mutant strains 
tested in this project. This strain 
contains a mutation in the Coq7/Cat5 
gene (a human Coq-7 homolog) that 
encodes DMQ hydroxylase, an enzyme 
necessary for the synthesis of 
ubiquinone (clk-1 (gene).2007). 
Ubiquinone, or coenzyme Q, is a critical 
component in the mitochondrial 
electron transport chain that, when 
removed, decreases ATP production in the 
mitochondria and causes stunted growth, slow 
Figure. 2.1 Biosynthetic pathway of 
ubiquinone in mitochondria, showing 
metabolic mutant defects (Hihi et al., 
2002) 
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movement and increased longevity in C. elegans (Hihi et al., 2002). Detailed mechanisms of the 
synthetic pathway can be seen in Figure 2.1. 
 Coq-3 (coq-3(ok506) IV/nT1 [qls51] (IV;V)) is the second of the metabolic mutants, and 
lacks 3,4-dihydroxy-5- hexaprenylbenzoate methyltransferase, an enzyme analogous to COQ-3, 
a mitochondrial enzyme that is involved in the synthesis of coenzyme Q10 (Coq-3 (gene), n.d.). 
These worms were provided by the C. elegans Reverse Genetics Core Facility at the University 
of British Columbia. This specific mutation is sex-linked and dominant, so the heterozygous 
dominant worms are tagged with GFP for correct identification. Homozygous recessive worms 
are non-viable. 
 Clk-1 and coq-3 strains were chosen to investigate different knockout mutations of 
enzymes directly involved in the electron transport chain. Each deals with a seperate part of the 
chain, but both directly influence coenzyme Q10 and its ability to function properly in the 
electron transport chain. These strains, when compared with AD strains under the same 
conditions and given the same treatments will allow the team to investigate the possibility of 
metabolic disruptions in Alzheimer’s Disease. 
2.1.3 Heat Shock to Induce Mutations 
 All strain of worms were initially grown at 20°C, then either eggs or L1 were passed onto 
new seeded plates. The amounts of worms that were passed onto these plates varied per assay 
being completed and were then placed into the 25°C incubator for 48-72 hours. After at least 36 
hours, the plates were taken out of the incubator and placed on the benchtop for 30 minutes 
before any testing began. The worms were then passed to the testing plate and each of the given 
assays were performed. During the testing the time, the plate was placed back into the incubator 
if more than one assay was being performed from the initial plate. After the first test was 
completed, the seeded plate was once again taken out of the incubator and allowed to sit on the 
benchtop for 10 minutes before testing. This process was repeated until all viable animals on 
each plate was tested (Adapted from Coyle, Nikolaki, & Ong, 2016).  
2.2 Addition of Derivatives to LB media and OP50 
2.2.1 Punicalagin  
 In order to create a solution with a final concentration of 1.2 x 10-7 M punicalagin 
(Oladije et al.,2014)  first 1.3 mg of punicalagin was weighed out using an analytical balance. 
This was then mixed 0.5 mL of 100% ethanol. After the powder was completely dissolved, then 
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99.5 mL of ultrapure MilliQ water was added to the same flask and mixed thoroughly. Then a 
1:10 dilution was performed with 10 mL of this first solution being added to 90 mL of ultrapure 
MilliQ water. After this dilution was performed, 10 mL of the second solution was filter 
sterilized using a 0.2 uM SteritopTM filter. Once sterile, a second 1:10 dilution was performed 
with the sterile 10 mL of the second solution and 90 mL of sterile, liquid LB media. This 
solution was then mixed thoroughly. This final solution was then inoculated with a single colony 
of OP50 E. coli, which was subsequently placed into a 37°C to incubate for a day. Once grown, 
this solution could then be seeded onto NGM plates and placed at room temperature to dry. All 
three solutions were then placed in the 4°C fridge until they were needed again.  
 2.2.2 Coenzyme Q10 
 Using an analytical balance, 1.03 mg of Coenzyme Q10 was weighed and then dissolved 
with 5 mL of 100% ethanol. This solution was then combined with 95 mL of ultrapure MilliQ 
water in order to achieve an initial concentration of 1.2 x 10-5 M. Then a 1:10 dilution was then 
performed with 10 mL of the initial solution and 90 mL of ultrapure MilliQ water. Once the 
second solution was mixed thoroughly, 10 mL was then filter sterilized using a 0.2 uM 
SteritopTM filter. Once this solution was sterilized, it was then added to 90 mL of sterile, liquid 
LB media which would allow for a final concentration of 1.2 x 10-7 M to be achieved. Once this 
final solution was made, it was inoculated with a single colony from a plate of OP50 E. coli and 
placed into the 37°C warm room for a day. After the liquid culture was grown up it was used to 
seed NGM plates at room temperature until they were dry. The first two solutions were placed in 
the -20°C while the liquid culture was placed in the 4°C fridge until further use.  
2.3 Assays 
2.3.1 Avoidance Assay 
 Ten young adult worms are picked onto an unseeded plate and allowed to adjust to this 
plate for approximately 1 minute. After the adjustment time has ended, the testing can begin 
through the use of two different solutions and the drop method.   
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Glass capillaries are then pulled apart with the 
use of a flame to soften the glass, and in order to make it 
fine tipped. This is then fixed in the mouth pipetting 
apparatus. The fine tip, that is now connected to the 
mouth pipetting apparatus, as can be seen in Figure 2.2. 
The needle is then placed in one of the solutions to 
collect a sample of it.      
A small drop is then placed near the tip of each 
tail of the forward moving worms. Capillary action then 
carries the solution up to the pharynx of the worm where 
one of two responses will be performed within 4 seconds 
after exposure to the solutions (Hilliard, Bargmann, 
& Bazzicalupo, 2002). An example of these 
responses can be seen in Figure 2.3. The first 
action, however, is a no avoidance response which 
is continued forward movement after the drop has 
been placed near the tail of the worm. While the 
second is an avoidance response which has three 
further classifications of an omega turn, full reversal, and a greater than 90° turn. Each strain was 
tested until an n of 10 had been achieved.  
 
Figure 2.3: A depiction of two different responses seen when testing the worms with the avoidance assay. A no 
avoidance response (A), typically seen with the solvent control, and an avoidance response (B), which would be 
seen with an experimental solvent, in the avoidance assay (Chute, 2013) 
Figure 2.2: A Mouth Pipette with a fine tipped needed 
used in Avoidance Assays. The red part is placed in 
the researchers mouth and liquid is take up in the 
needle on the clear end. The tip is then placed near 
the tail end of the worm in order to gauge their 
avoidance behavior. (Picture created by: Consedine, 
2018) 
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For the purposes of this study, M9 buffer and 0.1% SDS were being used to test for the 
avoidance response for each assay plate. The 0.1% SDS was made by mixing 995 μL of M9 
buffer with 5 μL of 20% SDS solution. M9 is a buffer solution that is used to wash C. elegans 
and this solution is being used as the solvent control. Sodium dodecyl sulfate, or more commonly 
known as SDS is a detergent typically used to denature proteins. In terms of C. elegans, 
however, it is a known repellant which should cause an avoidance response when exposed to this 
chemical.  After each drop is applied to tail of each worm, the response is noted in a lab 
notebook for every plate tested. The avoidance index is then calculated for each solution by 
dividing the number of avoidance responses by the total of number of drops. 
2.3.2 Chemotaxis Assay 
 One to two days prior, approximately 100 adult worms were transferred to a seeded OP50 
E. coli NGM plate, and stored in the appropriate temperature, 16°C, or 25°C. All worms will be 
coming from the 16°C fridge, however this is the time to relocate the worms to the incubator for 
heat shock if necessary. 
 On an unseeded NGM plate, a dot was made at the center with a marker; this is the 
origin. Two small circles, D and C should be 
made 180° apart from each other around the 
edges as can be seen in Figure 2.4. On each of 
the dots 1μL of sodium azide was placed on 
them as this compound can be used as a 
paralytic. On spot D, 1uL of 10-3 M diacetyl 
was added as well. On spot C, 1μL of DiH2O 
should be added. The plates should remain 
covered as they dried. 
  
 Using 1mL of S. Basal, a p1000 
pipetman, wash the plate of worms, and transfer the 
wash to a 1.5mL microfuge tube. After 5-10 
minutes, check that the worms have pelleted on the 
bottom of the tube, and aspirate off the remaining S. 
Basal. The worms in the tube should be washed 
Figure 2.4: Set up of Chemotaxis plate. D 
would be where diacetyl is added, C would 
be where water is added, and the origin is 
where the worms are added to the plate 
(Pictured created by: Randle, 2018).  
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with S. Basal two more times, followed by one wash of water. The water does not need to be 
aspirated off. 
 On one of the plates prepared with the chemicals, 10μL of worms suspended in the water 
wash were added to the plate on the origin. The remaining water is dried off gently with the 
corner of a kimwipe. There should be enough worms in the centrifuge tube to load approximately 
five plates. Experimental plates with worms are returned to the fridge or incubator for about 45 
minutes.  
 After 45 minutes of exposure to the chemicals, the plates are retrieved from the fridge or 
incubator and examined under a microscope. The number of worms at the chemical stimulus, 
spot D, are counted and noted in a lab notebook. The number of worms at the water control, spot 
C, are counted and recorded. The chemotaxis index is calculated by the following equation. 
  
 Equation 2.1: Equation for calculating chemotaxis index 
2.3.3 Locomotion Assay 
 Tests were run with five worms per plate on 35mm NGM 
plates seeded with OP50 E. coli LB media. Testing plates were 
prepared the day before running the assay. The plate seeding takes 
place near an open flame, where 2-4 drops of OP50 E. coli are 
placed on the plate using a Pasteur pipet. A lawn spreader (a bent 
Pasteur pipet) is dipped in ethanol, flamed, and then used in 
conjunction with a plate spinner to spread the lawn to cover the 
agar surface. Test plates are left to dry overnight at 23°C.  
 Worms were prepared the night before or morning of the 
assay. Sixty to seventy adult worms were picked to a seeded 
holding plate and were maintained at the same culture temperature 
until the assay began. To begin the assay, five worms were 
picked from the holding plate and placed in the center of an 
NGM test plate. Once the worms were on the test plate, the 
plate was placed on the camera stage as seen in Figure 2.5. 
Using the nematode tracking software Wormlab’ and the 
Figure 2.5: An Example of the Testing 
Plate on the Camera Stage during an 
experiment (Pictured created by: 
Consedine, 2018) 
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camera’s lenses, the focus and lighting were adjusted to see the worms clearly and with high 
contrast. Frames per second was set to 7.5, the duration to 20 minutes, and the resolution as high 
as possible. The worm tracker program was run. 
 Once finished, the recording needed to be prepared, tracked and repaired. The recording 
was opened in Wormlab for processing, as seen below in Figure 2.6. Threshold was increased to 
110-150 until all worms were highlighted in green, and the labeling tool was used to draw an 
oval in the non-highlighted portion of the agar. This restricted the tracking software to inside the 
label, to cover as much space as possible without touching green. The pen tool was used to 
individually label each worm, and tracking was restricted to the labeled region. At this point, 
each file would be ready for tracking, which could be done one recording at a time or 
sequentially, with a batch of multiple files. 
 
Figure 2.6: An Example of the WormLab Software tracking five adult worms, marked in green, during an 
experiment (Pictured created by: Consedine, 2018) 
2.3.4 ATP Bioluminescence Assay 
 The following procedure was adapted from Intracellular Assessment of ATP Levels in 
Caenorhabditis elegans by Palikaras and Taveranakis. From each treatment and temperature 
group, a full plate of adult worms of each species were washed off of a plate into a 1.5mL 
eppendorf tube with 1.5 mL of M9 buffer. Once in the eppendorf tube, they were allowed to sit 
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for 15 minutes until a “pellet” of worms formed at the bottom of the tube. Then 1 mL of this M9 
was taken out of the tube and disposed of. Once completed. Another 1 mL of M9 was added to 
the tube and again the tube was allowed to sit for an additional 15 minutes. Once this second 
wash was completed, 1450 μL was taken out and disposed of appropriately.  Using liquid 
nitrogen, the tubes were flash frozen with liquid nitrogen and then stored in the -80C freezer 
until the day of the assay (Palikaras & 
Tavernarakis, 2017).  
 When it is time to assay the 
worm samples for measurement, the 
frozen samples should be immersed in 
boiling water for 15 minutes, and then 
immediately incubated on ice for 5 
minutes. Using a temperature controlled 
centrifuge, the tubes should be 
centrifuged at 14,800 x G for 10 
minutes at 4°C. The supernatant was 
then transferred to a new 1.5mL tube. 
The supernatant was diluted using a 10 
fold dilution. The diluted samples were 
stored in the -20°C until the time of the 
assay, and kept on ice while in use. 
 An ATP Bioluminescence Assay 
Kit was purchased from Roche Scientific, 
and all chemicals were prepared 
according to the kit. 100uL of ATP standard, and M9 blank, and of each sample were loaded into 
individual 1.5mL tubes. The samples in the 1.5 mL tubes are transferred to an individual wells in 
a 96-well plate. Once all of them were added, 100 μL of luciferase is added to each sample as 
seen in Figure 3.7. 
Once the samples and lucerifase have been added to the well, the plate is placed in the 
PerkinElmer 2300 plate reader as seen in Figure 3.8 and the luminescence levels are read. This 
was repeated until all the samples have been measured. Luminescence and ATP levels are 
Figure 2.7: An example on how one would load the 96-
well plate with either a sample or luciferase for the ATP 
bioluminescence assay. An researcher will place the 
pipette tip on the edge of the well and add the 
sample/enzyme to that well by pressing on the top of the 
micropipette. (Pictured created by: Consedine, 2018)  
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directly correlated when using luciferase, meaning the higher the level of luminescence indicated 
the higher the amount ATP in the sample. This was repeated three times for each sample type for 
an n of 3 for each (Palikaras & Tavernarakis, 2017).  
 
Figure 2.8: An example on how the plate reader would be placed in the PerkinElmer 2300 plate reader. A 
researcher would then close the lid and run the program. After about thirty seconds, the researcher would have the 
luminescence values for each sample (Pictured created by: Consedine, 2018).  
 
 
 
 
  
 30 
 
3. Results and Discussion  
Following the methodology discussed above, the four different assays (the avoidance assay, the 
chemotaxis assay, mobility assay, and the ATP Bioluminescence assay) were performed on the 
five different strains of C. elegans. The strains were grown on the following conditions: OP50 E. 
coli, OP50 + Punicalagin, and OP50 + Coenzyme Q10. The results for these assays are reported 
throughout this chapter. 
3.1 Baseline testing  
 The baseline was obtained by testing the wild-type (N2), the transgenic Alzheimer’s 
Disease models CL2355 (pan-neuronal Aβ expression) and CL4176 (pan-muscular Aβ 
expression), and the metabolic mutant strains (coq-3, clk-1) in all four of the assays. The worms 
in this case were grown on NGM plates with OP50 E. coli.  
3.1.1 Avoidance Assay  
The avoidance assays tests the chemosensory abilities of these worms when exposed to a 
particular, aversive stimulus. In this assay only the N2, CL2355, coq-3, and clk-1 strains were 
tested. In this case all the worms were tested with 0.1% SDS as the aversive compound. Figure 
3.1 shows all the strains at both 16°C and 25°C when grown on untreated OP50. When testing 
the N2 worms grown at 16°C, the average avoidance index was 0.84 ± 0.030551 while testing 
the same strain at 25°C resulted in an average avoidance index of 0.83 ± 0.03. At both 
temperature conditions the coq-3 and clk-1 mutants each yielded similar average avoidance index 
values to wild-type 
worms. At 16°C, 
coq-3 and clk-1 both 
yielded a value of 
0.79 ± 0.01795. At 
25°C, coq-3 
produced an average 
avoidance index of 
0.82 ± 0.02 while clk-1 gave a value of 0.82 ± 0.01333.  
These values show that there was no observed aversive chemosensory deficit in either of 
the metabolic mutants when compared to wild-type values at either temperature when grown on 
untreated OP50. A defect was evident when the CL2355 AD model was tested. At 16°C this 
Figure 3.1: Average avoidance index 
for all strains in untreated conditions 
at 16◦C and 25◦C 
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strain produced a normal avoidance index of 0.82 ± 0.02. However, at 25°C, the CL2355 yielded 
an average avoidance index of 0.4 ± 0.021082 (p<0.0001). This value indicates that there is an 
apparent chemosensory defect when this particular strain is propagated at 25°C. This conveys 
that at this temperature the Aβ42 is hydrolyzed which results in chemosensory deterioration. This 
leads to a loss of response when exposed to an aversive stimulus such as SDS.   
3.1.2 Chemotaxis Assay  
 The chemotaxis assay, like the avoidance assay, also tests the chemosensory ability of the 
worms, however, it instead tests the attraction to a chemical stimulus. The N2, CL2355, clk-1, 
and coq-3 worms were tested with 10-3 M diacetyl as the chemical attractant. Like the avoidance 
assay, the chemotaxis assay tested worms at both 16°C and 25°C. The results of the chemotaxis 
assay at 16C and 
25C can be seen 
in figure 3.2. The 
wild-type N2 
worms had a 
chemotaxis index 
of 0.512 ± 0.0346 
at 16°C and 0.726 
± 0.0558 at 25°C 
(p=0.0027) The 
increase in chemotaxis index that is observed with the increase of temperature is due to the 
increased biochemical processes of the worms at higher temperatures. The CL2355 transgenic 
AD worms had a chemotaxis index of 0.474± 0.0511 at 16°C and 0.305 ± 0.0529 at 25°C 
(p<0.0001, p=0.0248). The clk-1 metabolic mutant worms have a chemotaxis index of 0.403± 
0.0247 at 16°C and 0.489 ± 0.6545 at 25°C (p=0.0183). The coq-3 metabolic mutant worms have 
a chemotaxis index of 0.389 ± 0.0467 at 16°C and 0.454 ± 0.0622 at 25°C (p=0.0061). Both of 
these strains experience a small increase in chemotaxis index as the temperature increases, as 
was observed in the N2 strain, however, this shift is not statistically significant.  
The observed chemotaxis index for the CL2355 worms decreases as the temperature 
increases. The increasing temperature results in the full expression of the Aβ protein that is 
expressed in this transgenic strain when exposed to heat. The full expression of the Aβ results in 
Figure 3.2: Average chemotaxis index 
for all strains in untreated conditions 
at 16◦C and 25◦C 
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the phenotype of decreased chemotaxis. The metabolic worms experience an overall deficit in 
chemotaxis index due to the lack of energy being produced, and thus lack of energy available for 
neuronal activity. The lack of energy production causes a decreased energy use. The chemotaxis 
assay looks specifically at neuronal activity, and a decrease chemotaxis index is indicative of 
decreased neuronal activity.   
3.1.3 Mobility Assay  
 The mobility assay measures average speed of five worms on an OP50 seeded NGM 
plate with no stimulus over the course of 20 minutes. These results are displayed in Figure 3.3 
below. Wild-
type N2 
worms 
grown at 
16°C 
measured a 
speed of 
80.24 ± 
3.826 µm/s, 
and at 25°C 
they were 
measured at 123.40 ± 11.68 µm/s (p<0.0001). This increase in mobility is due to the 
aforementioned increased metabolic rate when worms are grown at higher temperatures. The AD 
transgenic pan-muscular strain (CL4176) exhibited significantly impaired locomotion, with an 
average speed of 46.81 ± 3.826 µm/s (p=0.0027) when grown at 16°C and 39.36 ± 2.03 µm/s 
(p<0.0001) when grown at 25°C. Similarly, the pan-neuronal AD strain CL2355 measured a 
speed of 55.83 ± 3.42 µm/s (p=0.0269) at 16°C and 53.88 ± 2.81 µm/s (p<0.0001) at 25°C. 
Unlike the wild-type strain, the two AD strains showed a decrease in speed when grown at 25°C 
versus 16°C. The metabolic mutant clk-1 showed no significant change from wild-type with a 
speed of 72.39 ± 5.58 µm/s at 16°C, but had an average speed of 85.53 ± 5.55 µm/s (p=0.0003) 
when grown at 25°C, notably lower than N2 at 25°C. Like clk-1, coq-3 had a near wild-type 
mobility of 75.14 ± 6.67 µm/s at 16°C. Interestingly, coq-3 exhibited a drop in mobility at 25°C 
to 47.54 ± 2.35 µm/s (p<0.0001), not unlike the AD worms’ results. 
Figure 3.3: Average 
locomotion for all strains in 
untreated at 16◦C and 25◦C 
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Both AD strains’ levels of Aβ expression are temperature dependent, so increased growth 
temperature causes high levels of expression which negatively affects mobility. This explains 
why neither strain speeds up to same degree as N2. Additionally, coq-3 showed a drop in 
mobility--this effect is probably due to general energy deficiency as a result of the mutation in 
energy transduction pathways. It may not be severe enough to cause a drop in low temperature 
growth conditions, but the deficit is exacerbated when worms are heat shocked. As other 
biological enzymes become more efficient, the mutated enzyme remain inactive, creating the 
possibility for bottlenecks and overproduction, ultimately slowing the worm’s movement.  
3.1.4 ATP Bioluminescence Assay  
The ATP Bioluminescence Assay measures the amount of ATP in a particular mass of 
worms. All worm strains were tested for this assay and they were grown at both testing 
temperatures, similar to the other three assays. A visual representation of this data can be seen in 
Figure 3.4. When tested the wild-type worms (N2) had a calculated concentration of ATP of 
142.4 ± 52.66 µM at 16°C. While at 25°C this same strain had an ATP concentration of 109.3 ± 
20.26 µM. The coq-3 strain gave expected results for this assay at both temperatures. At 16°C 
these worms produced an ATP concentration of 152.9 ± 19.78 µM and at 25°C these same 
worms yielded a value of 83.73 ± 11.53 µM (p=0.0129). However at 16°C, the clk-1 worms 
yielded a value of 285.3 ± 71.27 µM and at the temperature upshift the resulting concentration 
was 138.5 ± 33 µM. A similar trend is once again observed in these worms as with the coq-3 
strain. The 
temperature 
upshift 
condition in 
the coq-3 
worms resulted 
in a much 
lower 
concentration 
of ATP than at 16°C. Both of these strains decreased at the higher temperature, in a similar 
manner that N2 does. This is indicating that at this higher temperature that all of these trains are 
Figure 3.4: ATP concentration 
comparison for all strains in untreated 
conditions at 16◦C and 25◦C 
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using more ATP than at the lower one. This suggests that all of their process on a cellular level 
would be sped up as a result of being grown at increased temperatures 
For the muscular AD model (CL4176), the measured values given at both temperatures 
were approximately the values of the N2 strain. These concentrations are as follows: at 16°C 
CL4176 yielded a value of 86.94 ± 11.29 µM and at 25°C they produced 108 ± 43.73 µM. 
Conversely, the pan-neuronal AD model (Cl2355) produced surprisingly higher values at both 
temperatures. At 16°C, these worms produced an ATP concentration of 249.3 ± 87.79 µM. 
While at the temperature upshift, CL2355 then yielded a value of 223.3 ± 40.07 µM. The 
CL4176 strain produced a slight increase in ATP levels, however, its calculated values are 
similar to the N2 values.  
The pan-neuronal AD model yielded approximately twice the amount of ATP compared 
to the wild-type at both temperatures. Based on this information, it can be suggested that the 
Aβ42 peptide is causing an overproduction of ATP within the organism. As this concentration is 
seen at both temperatures, it can then be assumed that the Aβ protein is not completely silenced 
at 16°C in either strain as well. The metabolic mutant worms both measured ATP concentrations 
approximately equal to the wild type worms even though the worms are mutated to disrupt ATP 
production. This was unexpected, but it must be noted that the assay only measures the 
momentary ATP concentration at a single point in time in a worm. This concentration is a 
function of both the rates of ATP production and use, and is not necessarily entirely indicative of 
either. However, it does give the experimenter a window into the general trends of the ATP-
producing metabolic processes and the opportunity for rough analysis. 
3.2 Punicalagin Treatment  
 To assess the effects of the potential therapeutics ability of punicalagin on both the AD 
transgenic models and metabolic mutants, all the worms were grown on plates with OP50 E. coli 
and punicalagin. These worms were then tested using the same experiments as before to see if 
this treatment was able to rescue the worms to normal behavioral phenotypes. 
 3.2.1 Avoidance Assay  
The same avoidance assay was used to test the worm’s avoidance response abilities when 
grown on OP50 E. coli and punicalagin at two different temperatures (16°C and 25°C). In the 
normal OP50 avoidance assay, it was observed that there was no significant difference between 
any of the strains when grown at 16°C, as can be seen in Figure 3.5. This same phenomenon was 
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again observed in this 16°C avoidance assay. They produced the following results as a result 
when tested with 0.1% SDS: N2 produced an avoidance index of 0.79 ± 0.0314, CL2355 
displayed a result of 0.85 ± 0.0342, clk-1 showed an avoidance index of 0.79 ± 0.0233, and coq-3 
had a result of 0.84 
± 0.0339. All of 
these values were 
expected to be 
similar as the 
untreated avoidance 
assays and were 
used as a control to 
make sure that the 
punicalagin treatment was not having any additional, aversive effects on the worms. 
 Previously, the 25°C avoidance assays showed that CL2355 had a significant decrease in 
avoidance response behavior. While the other two mutants being tested, clk-1 and coq-3, had a 
normal behavioral phenotype before treatment. Due to this the focus for this assay was to see if 
we could restore the CL2355 strain to the normal, wild-type avoidance behavior and see if there 
were any additional effects observed in the three other strains. The wild-type strain was tested 
once again as a control and produced an avoidance response of 0.82 ± 0.0249, as can be seen in 
Figure 3.6. The clk-1 and coq-3 mutants again produced avoidance indices at approximately the 
wild-type levels of 
0.78 ± 0.0326 and 
0.79 ± 0.0344. 
When tested in the 
avoidance assay, 
the CL2355 worms 
produced a result 
of 0.83 ± 0.0260 
(p<0.0001). 
This shows 
that through 
Figure 3.4 Average avoidance idex for all 
strains in both untreated and punicalagin 
treatment conditions at 16◦C 
Figure 3.6: Average avoidance 
index for all strains in both 
untreated and punicalagin 
treatment conditions at 25◦C 
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preventative treatment measures with a polyphenol such as punicalagin we were able to alleviate 
the effects of Aβ42. Typically, these worms have detrimental chemosensory ability, however, 
when treated with punicalagin were able to restore the Cl2355 model to normal chemosensory 
function, rescuing the avoidance phenotype of the CL2355 worms.      
 3.2.2 Chemotaxis Assay 
The Chemotaxis index of the worms was also measured at 16°C and 25°C after the 
worms were 
treated with 
punicalagin, 
these results can 
be seen in figure 
Q. At 16°C, the 
N2 worms 
experienced an 
increase, 
compared to 
untreated N2 worms at 16°C, in attractive chemosensory ability, showing a chemotaxis index of 
0.602 ± 0.0563. There was a slight increase in attractive chemosensory ability at 25°C, compared 
to 16°C, punicalagin treatment, producing a chemotaxis index of 0.621 ± 0.0573. This decrease 
is not a significant decrease and could be due to giving a healthy worm treatment that it does not 
need.  
 The chemotaxis index for the CL2355 strain remained constant, when exposed to 
punicalagin, at 16°C, measuring 0.462 ± 0.0432. There was a significant increase from the 
previously observed values at 25°C in attractive chemosensory ability, with a chemotaxis index 
of 0.699 ± 0.0680 (p=0.0002). Both the clk-1 and coq-3 mutant worms experienced increases in 
chemotaxis index, compared to no treatment, at both temperature conditions. For punicalagin 
treatment at 16°C, the clk-1 and coq-3 had chemotaxis indexes of 0.517 ± 0.0539 (p=0.0448) and 
Figure 3.7: Average chemotaxis index for all 
strains in both untreated and punicalagin 
treatment conditions at 16◦C 
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0.634 ± 0.0288 (p<0.0001), respectively. At 25°C, clk-1 had a chemotaxis index of 0.704 ± 
0.0395 
(p=0.0105) 
while Coq-3 
had a 
chemotaxis 
index of 0.716 
± 0.0554 
(p=0.0043).  
When 
given 
punicalagin as a dietary supplement, the attractive chemosensory ability in the Alzheimer’s 
Disease models and metabolic mutants of C. elegans was able to be rescued to the untreated, 
wild-type chemotaxis index of C. elegans. From previous research, we knew punicalagin was 
able to rescue the chemotaxis phenotype in Alzheimer’s model worms. This set of assays was 
able to show punicalagin’s positive effect on the metabolic mutants. Because of these observed 
rescues, we can also conclude that punicalagin is working in the ETC of the CL2355 strain. 
3.2.3 Mobility Assay  
Worms treated with punicalagin were tested on standard OP50 seeded NGM plates. N2 
worms on punicalagin at 25°C showed a slight decrease to 97.84 ± 12.01 µm/s (p=0.0267) 
compared to untreated worms, and N2 worms on punicalagin grown at 16°C move at 80.24 ± 
3.83 µm/s, as seen in Figure 3.9 and 3.10. Pan-muscular transgenic AD strain CL4176 grown on 
punicalagin showed a partial rescue in mobility, with an average speed of 52.84 ± 3.43 µm/s 
(p<0.0001, p=0.0004) at 25°C, and a small increase at 16°C from untreated to 64.35 ± 2.81µm/s 
(p=0.0017). However, the pan-neuronal transgenic AD strain CL2355 grown on punicalagin at 
25°C showed no significant rescue at 60.48 ± 1.65 µm/s (p<0.0001, p=0.0482), but CL2355 at 
16°C showed a slight increase to 78.10 ± 4.69 µm/s (p=0.0009). The metabolic strain clk-1 
showed a drop in speed with punicalagin at 25°C to an average of 58.95 ± 2.82 µm/s (p=0.001, 
p=0.0019), and no change from untreated at 16°C with a speed of 76.73 ± 5.41 µm/s. 
Conversely, coq-3 mutants on punicalagin moved faster than untreated worms, with a treated 
Figure 3.8: Average chemotaxis index for all 
strains in both untreated and punicalagin 
treatment conditions at 25◦C 
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speed of 72.60 ± 8.64 µm/s (p<0.0001) at 25°C, and an increase at 16°C to 97.64 ± 4.83 µm/s 
(p=0.0093).  
Although 
chemosensation in the 
AD models was 
successfully rescued by 
punicalagin at 25°C, 
general locomotion 
seems to be 
unaffected in the 
pan-neuronal model 
worms when Aβ is 
not fully expressed. 
Punicalagin seems to 
have a beneficial 
effect on the pan-
muscular mutant, 
suggesting that the 
compound may be 
relevant in regards to 
the muscular atrophy 
aspects of Alzheimer’s 
disease. However, it did not rescue the wild-type phenotype of normal movement, as rolling 
behavior was still observed and worms traveled in small circles. Finally, both metabolic mutants 
exhibited opposite reactions when treated with punicalagin. This indicates that the drug may 
have an effect on energy transduction pathways which is observable in general locomotion. 
 3.2.4 ATP Bioluminescence Assay  
 Based on the results to the behavioral assays above, we then wanted to see the effect of 
punicalagin treatment on ATP production in all of the strains. When treated with punicalagin 
there were several differences observed at both the testing temperatures. These differences can 
be observed in Figures 3.11 and 3.12. At 16°C the N2 worms tested had an increased ATP 
Figure 3.10: Average locomotion for 
all strains in both untreated and 
punicalagin treatment conditions at 
25◦C 
Figure 3.9: Average 
locomotion for all strains in 
both untreated and punicalagin 
treatment conditions at 16◦C 
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concentration of 207.2 ± 104.3 µM when given the punicalagin supplement. However when 
grown at 25°C the wild-type strain had almost the exact same concentration as the untreated 
condition. This concentration was measured to 109.5 ± 26.05 µM.  
The metabolic worms produced surprising results at both temperature conditions. The 
coq-3 strain produced a tremendous increase in the amount of ATP present when treated with 
punicalagin at 
both 
temperatures. 
These worms 
had a 
concentration 
of 555.6 ± 
161.05 µM 
(p=0.0146) at 
16°C while at 25°C they produced a concentration of 217.4 ± 56.58 µM (p=0.0432).The clk-1 
produced differing results when given the treatment at either temperature. At 16°C this strain had 
an ATP concentration of 403.2 ± 56.58 µM (p=0.0146) when given the treatment. While at 25°C 
the concentration was calculated at 82.35 ± 18.44 µM (p=0.0432). The transgenic AD models 
produced both differing and similar results. At 16°C, the pan-muscular model CL4176 increased 
while the pan-neuronal model CL2355 had a decrease in ATP production when given the 
treatment. However, at 25°C both of these models had a significant decrease in ATP production. 
The pan-muscular AD model produced concentrations of 154.8 ± 30.62 µM and 42.96 ± 6.957 
µM at 16°C and 25°C, respectively.  The CL2355 strain had a measured ATP concentration of 
151.5 ± 19.04 µM at 16°C, and 73.24 ± 20.17 µM (p=0.0121) at 25°C.  
 These results indicate that the treatment with punicalagin acts differently in each of the 
strains used. For the coq-3 mutant, the high values recorded suggest a massive overproduction of 
ATP and the coincidental misuse of ATP, as evidenced by the consistently low locomotion 
values. The clk-1 mutants experience an increase of ATP at 16C, but a decrease at 25C. The 
treatment may be working to increase ATP production in the metabolic worms, but at higher 
temperatures the worms use more energy, thus resulting in a lower ATP concentration. These 
results also show that amount of the ATP in both of the AD models can be reduced through the 
Figure 3.11: ATP concentration comparison 
for all strains in both untreated and 
punicalagin treatment conditions at 16◦C 
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use of punicalagin as a treatment. Specifically it shows that the severe overproduction of ATP in 
the CL2355 strain observed under untreated conditions at 25°C can be significantly reduced once 
given this 
treatment. This 
indicates that 
another 
consequence of 
Aβ may be 
alleviated 
through the use 
of this 
polyphenol as a form of treatment. However, for the CL4176 strain due to low amount of Aβ 
expression at 16°C this data suggests that this compound is causing the organism to slightly 
overproduce the amount of ATP compared to the wild-type levels.     
3.3 Coenzyme Q10 
In a similar manner to the assays tested with punicalagin, all the strains (N2, CL2355, 
CL4176, clk-1, and coq-3) were grown on OP50 E. coli with Coenzyme Q10. This happened at 
both temperatures in order to evaluate the effects of Coenzyme Q10 as a potential therapeutic 
measure for both Alzheimer’s Disease and general metabolic disorder. This was also done to see 
if we could rescue the strains to normal behavioral phenotype.   
 3.3.1 Avoidance Assay  
 This assay was again administered in the same way that was stated in the methodology 
and in the other sections in this section. The 16°C discussed previously showed that all the 
strains (N2, CL2355, clk-1, and coq-3) had the same approximate avoidance index. However, in 
order to see if Coenzyme Q10 had any additional effects, all the strains were tested when 
maintained at 16°C, the temperature in which no deficits are observed by any of the strains in a 
no treatment condition. The results from this assay at 16°C can be seen in Figure 3.13 and 
Figure 3.14. When treated with Coenzyme Q10, N2 producing an avoidance index of 0.82 ± 
0.0327. The other strains all produced similar values for this assay. The CL2355 strain generated 
an average avoidance index of 0.88 ± 0.0291. While the two metabolic mutants, clk-1 and coq-3, 
had an avoidance index value of 0.82 ± 0.0294 and 0.81 ± 0.0314 respectively. All of these 
Figure 3.12: ATP concentration comparison 
for all strains in both untreated and 
punicalagin treatment conditions at 25◦C 
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values were expected to be around these values and showed that the coenzyme Q10 treatment was 
not adversely affecting the 
chemosensory ability of all these 
strains.   
 The focus for this assay with 
this treatment condition was 
the CL2355 transgenic model 
at 25°C. This is again due to 
the fact that this was the only strain 
to show a decrease in chemosensory 
ability before treatment at this 
temperature condition as can be seen in Figure 3.1. While all the other strains being tested 
displayed a normal behavioral phenotype of this assay. Thus, it was expected that the N2, clk-1, 
and coq-3 strains would produce normal values for the avoidance index. The results for this can 
be seen in Figure 3.14. The wild-type worms (N2) produced a value of 0.81 ± 0.0233 for both 
this temperature 
and treatment 
condition. The 
clk-1 and coq-3 
strains also 
had similar 
avoidance 
index values 
of 0.79 ± 0.0179 
and 0.82 ± 0.0359. When tested the CL2355 strain produced a value of 0.83 ± 0.0260 
(p<0.0001).  
This value is approximately the avoidance index value of the wild-type C. elegans. This 
indicates that treatment with coenzyme Q10 was able to rescue the CL2355’s, the pan-neuronal 
AD model, chemosensory ability. As these worms typically have a significant decrease in 
avoidance behavior due Aβ plaques that are customarily present, this shows that these plaques 
are no longer having a detrimental effect due to coenzyme Q10 treatment. As coenzyme Q10 
Figure 3.13: Average avoidance 
index of all strains in both 
untreated and coenzyme Q10 
treatment conditions at 16◦C 
Figure 3.14: Average avoidance index of 
All Strains in both untreated and 
coenzyme Q10 treatment conditions at 
25◦C 
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works in the electron transport chain, these results support the claim that energy transduction is 
altered in Alzheimer’s model worms.  
 3.3.2 Chemotaxis Assay  
 Similar 
to the 
punicalagin 
treatment, 
coenzyme Q10 
treatment was 
also used to 
measure the 
effectiveness in 
rescuing 
chemosensory ability through the chemotaxis assay, these results are available in Figure 3.15 
and Figure 3.16. Like the punicalagin treatment, the coenzyme Q10 was tested as a supplement at 
both 16°C and 25°C temperature conditions. The wild-type N2 worms again saw a lower 
chemotaxis index value for 16°C when compared to 25°C. In addition to the decreased 
chemotaxis index when compared to the N2 worms that did not undergo any treatment. N2 
worms being treated with coenzyme Q10 had a chemotaxis index of 0.436 ± 0.0632 at 16°C and 
0.689 ± 0.0459 at 25°C. As hypothesized earlier, the decrease at the lower temperature is likely 
due to the slowed metabolic processes in the worm, and the slight decrease associated with the 
treatment is due to giving healthy worms an unnecessary supplement.  
 The transgenic Alzheimer’s Disease worms (CL2355) had an increase in chemotaxis 
index under both temperature conditions as compared to the same strain that did not undergo 
treatment. At 16°C the CL2355 strain had a chemotaxis index of 0.563 ± 0.0723 while the 25°C 
condition had a chemotaxis index of 0.665 ± 0.0612 (p=0.0003). The attractive chemosensory 
ability of the clk-1 metabolic mutant worms did not seem to be affected by coenzyme Q10 
treatment. At 16°C the chemotaxis index was 0.453 ± 0.0710 and at 25°C the chemotaxis index 
measured 0.497 ± 0.0412. The coq-3 metabolic mutants, however, were positively affected by 
coenzyme Q10 treatment, showing the classical full rescue to the wild-type chemotaxis index. At 
Figure 3.15: Average chemotaxis index of All 
Strains in both untreated and coenzyme Q10 
treatment conditions at 16◦C 
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16°C the worms had a chemotaxis index of 0.524 ± 0.0391 and at 25°C 0.622 ± 0.0442 
(p=0.0220).  
Both metabolic mutants were expected to be rescued by the coenzyme Q10 treatment as 
coenzyme Q10 works directly in the electron transport chain to produce ATP and both mutations 
that these worms have are 
in the production of the 
coenzyme Q in the 
electron transport chain. 
The coq-3 mutants 
acted as expected under 
the coenzyme Q10 
treatment. The lack of 
increase in chemotaxis 
index was not expected 
for clk-1 worms. The mutation these worms have occurs in different parts of the coenzyme Q 
production pathway, and may be by passed in coenzyme Q production if it is not working 
properly. The rescue of the CL2355 worms with the coenzyme Q10 contributes further to our 
conclusion that Alzheimer’s Disease worms have altered ATP production. 
 3.3.3 Mobility Assay  
 Wild-type N2 worms grown on coenzyme Q10 were the slowest of all 25°C wild-type 
trials, at 73.018 ± 3.826 µm/s, and showed no change at 16°C on coenzyme Q10, moving at 77.77 
± 6.77 µm/s. As seen in Figure 3.17 and Figure 3.18. This may due to a possible overloading of 
energy 
transduction 
pathways, 
specifically in the 
electron transport 
chain as 
coenzyme Q10 is 
an important 
factor. 
Figure 3.16: Average chemotaxis 
index of All Strains in both 
untreated and coenzyme Q10 
treatment conditions at 25◦C 
Figure 3.17: Average locomotion of all 
strains in both untreated and coenzyme 
Q10 treatment conditions at 16◦C 
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Supplementation of a healthy working system with a critical enzyme isn’t always beneficial--
over congestion effects may counteract any AD model benefits of the drug. CL4176 on 
coenzyme Q10 showed no change from untreated 25°C trials, at 37.22 ± 2.31 µm/s (p=0.0057), 
but showed an 
increase at 16°C 
from the untreated 
condition to 67.64 ± 
2.83 µm/s 
(p=0.0004). CL2355 
worms grown on 
coenzyme Q10 
showed a slight 
decrease to 44.99 ± 
1.91 µm/s (p=0.0104, p=0.0136) at 25°C, but like the muscular AD strain showed an increase 
from the untreated 16°C trials to 71.30 ± 2.55 µm/s (p=0.0012). Clk-1 metabolic mutants also 
were not rescued, with a treated speed at 25°C of 60.98 ± 6.07 µm/s (p=0.0080) and an 
unchanged treated speed at 16°C of 76.18 ± 4.30 µm/s. This could be because the clk-1 mutation 
is further upstream than the main coenzyme Q10 synthesis protein that is mutated in coq-3, which 
could mean there are further-reaching effects than just a coenzyme Q10 deficiency. Finally, coq-3 
worms grown on coenzyme Q10 produced a robust wild-type rescue, with a treated average speed 
of 128.82 ± 9.62 µm/s (p<0.0001) at 25°C and a surprisingly high speed of 129.29 ± 27.72 µm/s 
(p=0.0342, p=0.0005) at 16°C. This was expected, as coq-3 worms contain a mutated enzyme 
that facilitates he biosynthesis of coenzyme Q10, and as such can be rescued by simple 
supplementation with the missing product. 
Coenzyme Q10 was not successful in rescuing mobility in either AD model worm when 
heatshocked and fully expressing human Aβ. Additionally, it did not rescue clk-1 worms, 
possibly because the clk-1 mutation is further upstream than the main coenzyme Q10 synthesis 
protein that is mutated in coq-3. This means that there may be further-reaching effects than just a 
coenzyme Q10 deficiency. The drug did, however, rescue coq-3 worms back to wild-type levels. 
This was expected, as coq-3 worms contain a mutated enzyme that is directly responsible for the 
Figure 3.18: Average locomotion 
comparison of all strains in both 
untreated and coenzyme Q10 treatment 
conditions at 25◦C 
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biosynthesis of coenzyme Q10, and as such can be rescued by supplementation of the missing 
product. 
 3.3.4 ATP Bioluminescence Assay  
 Once we observed the results from the behavioral assays treated with coenzyme Q10, we 
then wanted to discover the effects of this supplement on the ATP concentrations in each of the 
strains. The worms were once again propagated on a plate seeded with OP50 and Coenzyme Q10 
at both temperatures in order to test this. The results for the coenzyme Q10 treatment at both 
temperature conditions can be seen in Figure 3.19 and 3.20.  Many differences were observed 
for each of the strains once treated with this compound. At both temperatures the wild-type strain 
was observed to have a large decrease in the ATP concentration when given this treatment. The 
amount of ATP was measured to 54.57 ± 13.7 µM at 16C and 18.1 ± 1.123 µM at 16°C and 
25°C. This data shows that the coenzyme Q10 treatment significantly decreases the amount of 
ATP present in these C. elegans when compared to their untreated values.  
 The metabolic mutant data is very peculiar compared to the other data collected. Each 
mutant had contrasting results at each temperature condition. The coq-3 worms had a large 
increase in ATP production at 16°C while at 25°C is significantly decreased. The ATP 
concentrations were calculated to 625.6 ± 224 µM and 35.29 ± 7.046 µM (p=0.0079) at 16°C 
and 25°C. This 16°C data indicates that a significant rise in ATP levels, which is what is 
expected when given this compound. However, we currently do not have an explanation for the 
25°C concentration. This value is very low compared to any of the other values and is 
unexpected. At the higher temperature we had expected for a significant amount of ATP to be 
present even though all metabolic process have increased. The only plausible explanation for this 
Figure 3.19: ATP concentration 
comparison of all strains in both untreated 
and coenzyme Q10 treatment conditions at 
16◦C 
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is that the supplement is causing either the ATP production to slowed so much that the process 
nearly stops or it is over producing so much that it eventually just causes this system to crash. A 
similar trend 
is observed in 
the clk-1 
mutant. At 
16°C, these 
worms 
produced an 
ATP 
concentration 
126.7 ± 40.74 µM. Conversely, at 25°C the clk-1 mutants had a measured amount of 184.4 ± 76 
µM (p=0.0393). T The AD transgenic models produced much different results than the 
metabolic mutants. At 16°C both strains displayed an increased in the ATP concentration while 
at 25°C they both decreased when compared to the untreated worms. The CL4176 strain 
produced a result of 169.9 ± 41.3 µM at 16°C and 64.02 ± 25.48 µM at 25°C. The pan-neuronal 
model produced values that had a similar trend. At 16°C, the Cl2355 worms had an ATP 
concentration of 631.6 ± 184 µM (p=0.0475) while at 25°C this same strain had a measured ATP 
value of 44.33 ± 5.298 µM (p=0.0013).   
The 25°C data is what was expected with this supplement while the 16°C was not. As 
clk-1 has a mutation in the electron transport chain, it was completely expected that coenzyme 
Q10 would cause them to have have increase in ATP levels at both temperature conditions. Even 
though both of these values are around the untreated wild-type levels, there is no explanation as 
to why this strain increased under one temperature and decreased under another. However, based 
on the results it appears that at lower temperatures this compound slows down the ATP 
production process to a small extent, around what would be observed in untreated conditions. 
The data shows that when given treatment with coenzyme Q10 that there is a significant decrease 
in the amount of ATP when compared to untreated conditions at 25°C. This then indicates that 
this supplement is able to alleviate the overproduction side effects of the AB plaques. Based on 
the punicalagin data it would have been expected both of these conditions would decrease as 
well. However the exact opposite is seen, thus the only plausible explanation for this is that the 
Figure 3.20: ATP concentration 
comparison of all strains in both untreated 
and coenzyme Q10 treatment conditions at 
25◦C 
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supplement treatment is causing the faulty ATP production system to severely increase the 
amount of ATP in the organism.   
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4. Conclusions and Future Work 
4.1 Conclusions 
The results obtained over the course of this project paint an interesting picture for two 
potential treatments for Alzheimer’s Disease. In this project, three behavioral assays and one 
biochemical ATP assay were performed on transgenic AD-type and metabolic mutant strains of 
C. elegans. Avoidance and chemotaxis assays were used to test chemosensation while 
locomotion assays quantified mobility. Through these assays, deficits in chemosensation and 
locomotion were observed in both AD and metabolic mutant strains, confirming the validity of 
these assays for the measurement of behavioral phenotypes. Additionally, phenotypic deficits of 
impaired chemosensation and locomotion in the AD model worms mirror those found in human 
AD patients, further supporting the use of transgenic AD strains as a model system. Metabolic 
mutants exhibited significant mobility impairments and showed deficits in the chemotaxis assay, 
so they served as a suitable counterpart to the AD worms in the comparison of treatment efficacy 
and mechanism of action. Additionally, the project employed a bioluminescent ATP assay to 
quantify ATP levels in each strain under non-treated and treated conditions in order to further 
explore the role of energy transduction in Alzheimer’s Disease. All untreated strains showed 
wild-type levels except for the pan-neuronal AD strain CL2355, which showed a twofold 
increase in measured ATP levels. This baseline value indicates that ATP production in worms 
expressing Aβ is much higher than normal, supporting the initial theory of metabolic disruption. 
        The results obtained in this project also indicate that punicalagin is able to successfully 
rescue chemotaxis defects due to expression of human Aβ in the pan-neuronal AD strain. Pan-
muscular AD worms were not tested in the chemosensory behavioral assays, but showed only a 
small mobility rescue, as did the pan-neuronal AD worms. This suggests that this treatment is 
able to partially rescue locomotion, but not fully to wild-type levels. Chemotactic deficits in the 
metabolic mutants were also rescued to wild-type levels by punicalagin, suggesting that the 
compound is active in the electron transport chain to some extent. This conclusion is further 
supported by the locomotion assay results, which showed a partial rescue in coq-3 and a decrease 
in mobility in clk-1. Although the effects were not necessarily positive, they support the 
hypothesis that punicalagin has an effect in energy transduction pathways. 
ATP bioluminescence assays performed on AD worms treated with punicalagin show a 
decrease in ATP concentration in both strains. Most notably, pan-neuronal AD worms show a 
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decrease back to wild-type ATP levels, indicating that punicalagin was able to rescue a normal 
metabolic phenotype, at least with regards to ATP production. The mechanism of action of 
punicalagin is not currently known, but it is a known antioxidant. One possible explanation 
involves the suppression of reactive oxygen species associated with Aβ accumulation and 
neuronal damage. This falls in line with earlier data; if punicalagin can inhibit harmful effects of 
Aβ accumulation, it would prevent neuronal degradation and effectively rescue neuronal function 
and chemotaxis. Additionally, the ATP assays for the metabolic strains showed alternate effects 
in either strain: coq-3 increased when treated, and clk-1 decreased when grown on punicalagin. 
While the results are not consistent as to punicalagin’s effect on the electron transport chain, 
there is a clear and significant difference between treated and untreated worms, indicating that it 
has an effect on energy transduction. 
Results also indicated that coenzyme Q10 is able to rescue chemosensation in pan-
neuronal AD worms. Both chemotaxis and avoidance assays show a robust wild-type rescue. 
However, coenzyme Q10 treatment does not rescue mobility, and actually causes a slight 
decrease in mobility in neuronal AD worms. The metabolic mutants displayed similar results to 
the AD model worms, but only showed a defect in the chemotaxis assay and mobility assays, and 
not the avoidance assay. However, neither strain of metabolic mutants was able to be rescued in 
the chemotaxis assay. This indicates that coenzyme Q10 may not be directly involved in neuronal 
signaling, but is somehow involved in mediating the effects of neurodegeneration in Aβ-
expressing neurons. ATP data obtained for coenzyme Q10 showed the same effects as 
punicalagin in the pan-neuronal AD strain. ATP levels were again reduced from twice wild-type 
values to wild-type levels. Coenzyme Q10 is a known coenzyme in the electron transport chain, 
so this may indicate that the electron transport chain is directly involved in effecting the 
Alzheimer’s Disease phenotype in C. elegans. ATP values for metabolic mutants returned 
strange values, as coq-3 ATP levels decrease and clk-1 levels increased when treated. Coenzyme 
Q10 is deficient in both mutants, but doesn’t necessarily cause a return to wild-type ATP levels. 
This is due to the fact that the measured values of ATP don’t tell the whole story. 
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Fig. 4.1: Conceptual understanding of ATP bioluminescence assays 
    The ATP data obtained illuminated a part of energy transduction in the transgenic AD worms. 
Measured ATP concentrations show an instantaneous state of the system, which is normally in a 
dynamic equilibrium in live worms. This equilibrium, as can be seen in Figure 4.1 above, is a 
function of both ATP production rates and ATP usage rates. The N2 worms provided a baseline 
ATP concentration in healthy worms. The metabolic worms both exhibited decreased ATP 
production, however, their ATP concentration was equal to the wild type as these worms seem to 
have an adapted equilibrium, balancing low ATP production with low use through slowed 
movements. These worms use less ATP, as exhibited in the behavioral assays, to maintain a 
healthy ATP homeostasis. In the behavioral assays, the CL2355 works also exhibited decreased 
ATP usage, but in the ATP bioluminescence assay, the same worms had a significantly higher 
concentration of ATP. These worms did not have an increased ATP use to couple their increased 
ATP production, causing a disrupted ATP equilibrium. The use of the bioluminescence assay 
provided us with information to understand how ATP is being produced and processed in C. 
elegans models of Alzheimer’s Disease. 
4.2 Future Work 
    The research conducted yielded a deeper understanding on the metabolic homeostasis that 
regulates ATP levels in the Alzheimer’s Disease worm models. Additionally, more work needs 
to be done to continue to uncover all of the changes that occur in the metabolism of Alzheimer’s 
Disease in this C. elegans model. To accomplish this, a comprehensive metabolic analysis needs 
to be performed. The ATP bioluminescence assays gave us a glimpse of the ATP concentration 
in the entirety of the worm at a specific time. The metabolic analysis should look at worms under 
different conditions that would affect energy uses. Different metabolites, including NADH and 
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FADH2 should be studied to build a larger picture of energy transduction in Alzheimer’s 
Disease. The metabolite analysis should be adapted from the ATP bioluminescence assay to 
focus more specifically on the mitochondria in neurons, as opposed to entire worm lysate. This 
process could be difficult in worms due to their size, so a different model organism would need 
to be considered. Finding a way to perform this type of assay successfully will allow energy in 
neurons of Alzheimer’s Disease patients to be better characterized. From this research, more 
information on the mechanisms of each treatment could be gathered to allow for further 
understanding on the metabolism in AD.  
    Punicalagin and Coenzyme Q10 were able to rescue both attractive and aversive chemosensory 
ability in the Alzheimer’s Disease model C. elegans strains. We only tested the treatments at one 
concentration and as a dietary supplement that the worms were constantly exposed to. To further 
understand both punicalagin and coenzyme Q10’s effectiveness in alleviating symptoms of 
Alzheimer’s Disease there are multiple future projects that can be completed to learn more. One 
would be to vary the concentration in order to see the upper and lower limits of each supplement 
that can produce a phenotypic rescue. The same behavioral assays could be used at a variety of 
higher and lower concentrations. Additionally, both supplements should be tested as both a 
symptomatic and a restorative treatment options. This could also be completed using the same 
assays but adapting to test the same worms multiple times. For preventative treatment, the worms 
would be exposed to the punicalagin from the start and behavior would be analyzed, as done in 
this study. After the first behavior analysis, worms would then be moved to an untreated plate for 
1-2 days and then tested again. For restorative treatment, worms would be grown on non-treated 
plates to adulthood and then tested for behavior. After this baseline testing, they would be given 
a treatment for 1-2 days and retested.  
    Additionally, neither of the treatments were successful at treating the deficit in the mobility 
phenotype in the AD model C. elegans. There could be other polyphenols and other dietary 
supplements that could induce aid in mobility. There is more research that suggests potential 
therapeutics in terms of mobility restoration. Additionally, the further metabolite analysis 
mentioned previously could help lead to the discovery of a potential therapeutic. Testing of the 
mobility in C. elegans could also be furthered analyzed using the different methods available in 
the Worm Tracker software, including thrashing, reversals, general orientation/pathfinding, and 
turning frequency, to better test potential treatments  
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